scholarly journals INFERTILITY MANAGEMENT THROUGH AYURVEDA SHODHANA KARMA- A CASE REPORT

2019 ◽  
pp. 171-173
Author(s):  
Pooja .S. Dhuria ◽  
Prathima
Keyword(s):  
Treatment Options ◽  
Female Infertility ◽  
Reproductive Age ◽  
World Health ◽  
Clinical Feature ◽  
Traditional System ◽  
The World ◽  
One Year ◽  
Health Organization ◽  
Consecutive Cycle

Purpose: The World Health Organization (WHO) estimate that 60 to 80 million couples worldwide currently suffer from infertility. The female infertility has becomes major issue in current scenario due to the increasing number of incidences day by day. In India alone many couples suffers from infertility. The treatment options of female infertility also improving and traditional system of medicine such as Ayurveda describes female infertility broadly with its treatment protocol.Infertility affects women of reproductive age group all over the world. The infertility can be primary or secondary. Panchakarma can treat infertility successfully using various methods along with Ayurvedic formulations. Methodology: A Female Patient of 26 year came to OPD presenting with the complaints of inability to Conceive. Patient was complaining of delayed and heavy menstrual Periods as a clinical feature of PCOD which was diagnosed in USG report Patient was treated with Panchakarma and Ayurvedic Oral medicine. Vamana karma was done and in next Consecutive Cycle Patient got conceived. Result: In next Consecutive Cycle Patient got conceived and she is under regular Antenatal check up. Conclusion: Infertility is defined as a failure to conceive within one year or more years of regular unprotected coitus. PCOD occurs due to an imbalance caused by any of the three Doshas which affect the fertility of the female. These causes increase of Kapha and Vata Dosha and cause the formation of the multiple cysts in ovaries leading to anovulatory periods followed by obesity, hirustitsm. Vamana Karma helps in Strotoshudhi and help in the kapha disorders. Pushpadhanwa rasa act on the Manashanthi and Garbhakrut. Ashwagandha Ksheerpaka acts as Garbhasthapaka and Rasayana. The present study reveals the effective management of infertility associated with PCOD was managed by Shodana and Garbhasthapaka oushadhi KEYWORDS: PCOS, Artava Dusti ,Sthoulya, Infertility

Preventing Premature Weaning: Management Options for Common Lactation Conditions, Including OMT

2020 ◽  
pp. 20-25
Author(s):  
Denise Sackett ◽  
Tala Dajani ◽  
David Shoup ◽  
Uzoma Ikonne
Keyword(s):  
Postpartum Depression ◽  
Family Physician ◽  
Treatment Options ◽  
World Health ◽  
Management Options ◽  
Pharmacological Management ◽  
Control And Prevention ◽  
Lactational Mastitis ◽  
One Year ◽  
Health Organization

The benefits of breastfeeding are well established. The World Health Organization and the Centers for Disease Control and Prevention recommend that mothers breastfeed infants for at least one year, but most children are not breastfed that long because of many factors. Breastfeeding mothers face many challenges to continued breastfeeding, including medical conditions that arise during this period, such as postpartum depression and lactational mastitis. Because of a perceived lack of consistent guidance on medication safety, it can be difficult for the family physician to treat these conditions while encouraging mothers to continue breastfeeding. The purpose of the current review is to summarize and clarify treatment options for the osteopathic family physician treating lactating mothers. We specifically focus on the pharmacological management of contraception, postpartum depression, and lactational mastitis.

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

2020 ◽  
Author(s):  
Lara Bittmann
Keyword(s):  
World Health Organization ◽  
Clinical Picture ◽  
Treatment Options ◽  
World Health ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

scholarly journals Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia

2021 ◽  
Vol 45 (1) ◽  
Author(s):  
Heba K. Nabih
Keyword(s):  
Passive Immunization ◽  
Immunoglobulin Therapy ◽  
World Health ◽  
Clinical Feature ◽  
Main Body ◽  
Plasma Therapy ◽  
Rapid Spread ◽  
The World ◽  
Health Organization

Abstract Background The global coronavirus disease 2019 (COVID-19) was announced as pandemic by the World Health Organization (WHO). With the increased number of infected and dead victims daily all over the world, it becomes necessary to stop or overcome its rapid spread. Main body Although the production of vaccine or even specified effective anti-virus may take about six months to a year, intravenous immunoglobulin (IVIg) may be clinically used as a safe treatment to save and improve the quality of life of patients with a variety of immunodeficiency diseases such as lymphocytopenia, which is a common clinical feature in COVID-19. Conclusion Through the current review, it was concluded that this passive immunization may promote the immunity to better fight against the virus, so the survival of the patients could be kept longer. The efficacy of immunotherapy with IVIg would be greater if the immune IgG antibodies were collected from convalescent plasma therapy.

scholarly journals A review of post infectious pulmonary fibrosis in the era of COVID-19 and potential treatment options

2021 ◽  
Vol 9 (40) ◽  
pp. 37-46
Author(s):  
Medha Ghose ◽  
Maehali Patel
Keyword(s):  
Risk Factors ◽  
Pulmonary Fibrosis ◽  
Treatment Options ◽  
World Health ◽  
Potential Treatment ◽  
Pulmonary Injury ◽  
The World ◽  
Health Organization ◽  
Post Infectious

On March 11, 2020, the World Health Organization (WHO) released a statement characterizing COVID-19 as a pandemic that has, as of October 2020, caused almost 36 million confirmed global cases and over 1 million deaths. One of the long-term complications suggested by researchers is fibrosis. It has been hypothesized that the combination of ongoing pulmonary injury caused by COVID-19 and the inability to promptly repair damage results in interstitial matrix widening and eventual compression and destruction of alveoli and capillaries. Here we focus on pathogenesis, risk factors, different infectious causes of fibrosis along with COVID-19, and potential treatment options that might reduce its effects. Key words: COVID-19, pulmonary fibrosis, mechanism, treatment

scholarly journals Pandemic 2011: coming soon to a location near you.

2021 ◽  
Author(s):  
Jennifer Sacco
Keyword(s):  
Media Coverage ◽  
World Health ◽  
First Case ◽  
The World ◽  
Spanish Flu ◽  
Seasonal Flu ◽  
The Media ◽  
One Year ◽  
Health Organization ◽  
Lower Death Rate

"H1 N1 is a virus that has been sensationalized by the media since the first case was discovered in Mexico during the spring of 2009. People around the world feared that the virus would mutate into something as severe as the 1918 Spanish flu, one of the deadliest plagues in history. However experts had discovered by June of 2009 that the Spanish flu was not comparable to H1 N1. Yet for six months newspaper reporters continued to compare the ew epidemic to the Spanish flu, thus keeping alive the threat of an unstoppable pandemic. One year has passed since the first case of H1 N1 was confirmed. After all of the attention that H1 N1 received, it proved to be not much different than a typical seasonal flu, resulting in a lower death rate (Schabas and Rau, 2010). Recently, a number of investigations have begun to determine if the World Health Organization (WHO) overemphasized the level of risk, resulting in a large quantity of sensationalized media coverage, and citizens in a state of panic.

scholarly journals Heterogeneity of the COVID-19 epidemic in Australia: What can we learn from it?

2021 ◽  
Author(s):  
Qiuli Chen ◽  
Yibeltal Assefa
Keyword(s):  
Public Health ◽  
Good Governance ◽  
System Capacity ◽  
World Health ◽  
Contact Tracing ◽  
South Wales ◽  
The World ◽  
Effective Community ◽  
One Year ◽  
Health Organization

Abstract It has been more than one year since the World Health Organization declared the pandemic of COVID-19. Countries around the world are still struggling to control their epidemics. Australia has shown its resilience in the fight against the epidemic by providing a comprehensive response involving the whole-of-government and whole-of-society. Despite the overall successful national response, the epidemic in Australia has been heterogeneous across states. We conducted a mixed-methods study to analyze the epidemic and explain the variable manifestation of the epidemic across states in Australia. Most of the COVID-19 cases and deaths were in Victoria and New South Wales states due to differences in governance of the epidemic and public health responses (quarantine and contact tracing) among states. Countries could learn not only from Australia’s overall successful response, through good governance, effective community participation, adequate public health and health system capacity and multisectoral actions, but also from the heterogeneity of the epidemic among states. Successful response to epidemics in countries with a decentralized administration requires multi-level governance with alignment and harmonization of the response.

scholarly journals Duration of birth interval and its predictors among reproductive-age women in Ethiopia: Gompertz gamma shared frailty modeling

PLoS ONE ◽  
2021 ◽  
Vol 16 (2) ◽  
pp. e0247091
Author(s):  
Getayeneh Antehunegn Tesema ◽  
Misganaw Gebrie Worku ◽  
Achamyeleh Birhanu Teshale
Keyword(s):  
World Health Organization ◽  
Birth Interval ◽  
Information Criteria ◽  
Reproductive Age ◽  
World Health ◽  
Modern Contraceptive ◽  
Reproductive Age Women ◽  
The World ◽  
Shared Frailty ◽  
Health Organization

Background The World Health Organization recommended a minimum of 33 months between consecutive live births to reduce the incidence of adverse pregnancy outcomes. Poorly spaced pregnancies are associated with poor maternal and child health outcomes such as low birth weight, stillbirth, uterine rupture, neonatal mortality, maternal mortality, child malnutrition, and maternal hemorrhage. However, there was limited evidence on the duration of birth interval and its predictors among reproductive-age women in Ethiopia. Therefore, this study aimed to investigate the duration of birth interval and its predictors among reproductive-age women in Ethiopia. Methods A secondary data analysis was conducted based on the 2016 Ethiopian Demographic and Health Survey data. A total weighted sample of 11022 reproductive-age women who gave birth within five years preceding the survey was included for analysis. To identify the predictors, the Gompertz gamma shared frailty model was fitted. The theta value, Akakie Information Criteria (AIC), Bayesian Information Criteria (BIC), and deviance was used for model selection. Variables with a p-value of less than 0.2 in the bi-variable analysis were considered for the multivariable analysis. In the multivariable Gompertz gamma shared frailty analysis, the Adjusted Hazard Ratio (AHR) with a 95% Confidence Interval (CI) was reported to show the strength and statistical significance of the association. Results The median inter-birth interval in Ethiopia was 38 months (95% CI: 37.58, 38.42). Being living in Addis Ababa (AHR = 0.15, 95% CI: 0.03, 0.70), being rural resident (AHR = 1.13, 95% CI: 1.01, 1.23), being Muslim religious follower (AHR = 6.53, 95% CI: 2.35, 18.18), having three birth (AHR = 0.51, 95% CI: 0.10, 0.83), having four birth (AHR = 0.30, 95% CI: 0.09, 0.74), five and above births (AHR = 0.10, 95% CI: 0.02, 0.41), and using contraceptive (AHR = 2.35, 95% CI: 1.16, 4.77) were found significant predictors of duration of birth interval. Conclusion The length of the inter-birth interval was consistent with the World Health Organization recommendation. Therefore, health care interventions that enhance modern contraceptive utilization among women in rural areas and Muslim religious followers would be helpful to optimize birth interval.

scholarly journals Biomedical engineering and ethics: reflections on medical devices and PPE during the first wave of COVID-19

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Alessia Maccaro ◽  
Davide Piaggio ◽  
Concetta Anna Dodaro ◽  
Leandro Pecchia
Keyword(s):  
Ethical Dilemmas ◽  
World Health ◽  
Protective Equipment ◽  
Allocation Of Resources ◽  
Ethical Implications ◽  
Global Pandemic ◽  
The World ◽  
One Year ◽  
Health Organization ◽  
Clinical Engineers

AbstractIn March 2019, the World Health Organization (WHO) declared that humanity was entering a global pandemic phase. This unforeseen situation caught everyone unprepared and had a major impact on several professional categories that found themselves facing important ethical dilemmas. The article revolves around the category of biomedical and clinical engineers, which were among those most involved in dealing with and finding solutions to the pandemic. In hindsight, the major issues brought to the attention of biomedical engineers have raised important ethical implications, such as the allocation of resources, the responsibilities of science and the inadequacy and non-universality of the norms and regulations on biomedical devices and personal protective equipment. These issues, analyzed one year after the first wave of the pandemic, come together in the appeal for responsibility for thought, action and, sometimes, even silence. This highlights the importance of interdisciplinarity and the definitive collapse of the Cartesian fragmentation of knowledge, calling for the creation of more fora, where this kind of discussions can be promoted.

scholarly journals ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential

2021 ◽  
Vol 14 (7) ◽  
pp. 655
Author(s):  
Subrata Deb ◽  
Anthony Allen Reeves ◽  
Robert Hopefl ◽  
Rebecca Bejusca
Keyword(s):  
Drug Interaction ◽  
Ebola Virus ◽  
Treatment Guidelines ◽  
Treatment Options ◽  
World Health ◽  
Nucleoside Triphosphate ◽  
Treatment Regimens ◽  
Global Pandemic ◽  
The World ◽  
Health Organization

On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems, administrations, and treatment ingenuity across the world. COVID-19 is caused by the novel beta coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Since the inception of the pandemic, treatment options have been either limited or ineffective. Remdesivir, a drug originally designed to be used for Ebola virus, has antiviral activity against SARS-CoV-2 and has been included in the COVID-19 treatment regimens. Remdesivir is an adenosine nucleotide analog prodrug that is metabolically activated to a nucleoside triphosphate metabolite (GS-443902). The active nucleoside triphosphate metabolite is incorporated into the SARS-CoV-2 RNA viral chains, preventing its replication. The lack of reported drug development and characterization studies with remdesivir in public domain has created a void where information on the absorption, distribution, metabolism, elimination (ADME) properties, pharmacokinetics (PK), or drug-drug interaction (DDI) is limited. By understanding these properties, clinicians can prevent subtherapeutic and supratherapeutic levels of remdesivir and thus avoid further complications in COVID-19 patients. Remdesivir is metabolized by both cytochrome P450 (CYP) and non-CYP enzymes such as carboxylesterases. In this narrative review, we have evaluated the currently available ADME, PK, and DDI information about remdesivir and have discussed the potential of DDIs between remdesivir and different COVID-19 drug regimens and agents used for comorbidities. Considering the nascent status of remdesivir in the therapeutic domain, extensive future work is needed to formulate safer COVID-19 treatment guidelines involving this medication.

scholarly journals Potential Antiviral Options against SARS-CoV-2 Infection

Viruses ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 642 ◽  
Author(s):  
Aleksandr Ianevski ◽  
Rouan Yao ◽  
Mona Høysæter Fenstad ◽  
Svetlana Biza ◽  
Eva Zusinaite ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Broad Spectrum ◽  
Treatment Options ◽  
Neutralization Assay ◽  
World Health ◽  
The World ◽  
Emerging Treatments ◽  
Novel Virus ◽  
Health Organization ◽  
Respiratory Coronavirus

As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.

Sign in / Sign up

Export Citation Format

Share Document